Literature DB >> 2594683

Quantitative whole-body autoradiographic determination of tacrine tissue distribution in rats following intravenous or oral dose.

W McNally1, M Roth, R Young, H Bockbrader, T Chang.   

Abstract

Tacrine (1,2,3,4-tetrahydro-9-acridinamine) has been employed in diverse clinical situations but has recently been of considerable interest for the treatment of cognitive deficits associated with senile dementia (Alzheimer's disease). The present studies examined tissue distribution of radiolabeled tacrine by quantitative whole-body autoradiography. Tacrine radioequivalents were widely distributed to tissue following iv or peroral dose, with an apparently prolonged absorption phase following po dose. The presence of high levels of activity in kidneys and ureters indicates a major role for urinary excretion, but there is also evidence for biliary excretion and direct secretion of compound or metabolites into the intestinal lumen. Tacrine was rapidly taken up into the brain and demonstrated regional localization to cortex, hippocampus, thalamus, and striatum. Although the inhibition of acetylcholinesterase by tacrine is well documented, regional uptake in brain did not correlate consistently with distribution of the enzyme, supporting suggestions by others that the alleged action of tacrine in treatment of senile dementia may be by mechanisms other than cholinesterase inhibition.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2594683     DOI: 10.1023/a:1015933210803

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  Estimation and urinary excretion of tetrahydroaminoacridine.

Authors:  P N KAUL
Journal:  J Pharm Pharmacol       Date:  1962-04       Impact factor: 3.765

2.  The pharmacology of some new anti-cholinesterases.

Authors:  F H SHAW; G A BENTLEY
Journal:  Aust J Exp Biol Med Sci       Date:  1953-12

3.  Some aspects of the pharmacology of morphine with special reference to its antagonism by 5-amino-acridine and other chemically related compounds.

Authors:  F H SHAW; G BENTLEY
Journal:  Med J Aust       Date:  1949-12-17       Impact factor: 7.738

4.  9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current.

Authors:  B Drukarch; K S Kits; E G Van der Meer; J C Lodder; J C Stoof
Journal:  Eur J Pharmacol       Date:  1987-09-02       Impact factor: 4.432

5.  Tetrahydroaminacrine in anaesthesia.

Authors:  A R Hunter
Journal:  Br J Anaesth       Date:  1965-07       Impact factor: 9.166

Review 6.  THA--a review of the literature and its use in treatment of five overdose patients.

Authors:  W K Summers; K R Kaufman; F Altman; J M Fischer
Journal:  Clin Toxicol       Date:  1980-05       Impact factor: 4.467

7.  Enhancement of memory by physostigmine.

Authors:  K L Davis; R C Mohs; J R Tinklenberg
Journal:  N Engl J Med       Date:  1979-10-25       Impact factor: 91.245

8.  Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease.

Authors:  B Drukarch; J E Leysen; J C Stoof
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

9.  Oral physostigmine and lecithin improve memory in Alzheimer disease.

Authors:  L J Thal; P A Fuld; D M Masur; N S Sharpless
Journal:  Ann Neurol       Date:  1983-05       Impact factor: 10.422

10.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

Authors:  W K Summers; L V Majovski; G M Marsh; K Tachiki; A Kling
Journal:  N Engl J Med       Date:  1986-11-13       Impact factor: 91.245

View more
  9 in total

Review 1.  Acetylcholinesterase inhibitors in Alzheimer's disease.

Authors:  B M McGleenon; K B Dynan; A P Passmore
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  A recursive-partitioning model for blood-brain barrier permeation.

Authors:  S R Mente; F Lombardo
Journal:  J Comput Aided Mol Des       Date:  2005-12-06       Impact factor: 3.686

3.  High-affinity [3H]THA (tetrahydroaminoacridine) binding sites in rat brain.

Authors:  E E Mena; M C Desai
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

Review 4.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of tacrine.

Authors:  S Madden; V Spaldin; B K Park
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

Review 6.  Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.

Authors:  A J Wagstaff; D McTavish
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

7.  Spatial Quantitation of Drugs in tissues using Liquid Extraction Surface Analysis Mass Spectrometry Imaging.

Authors:  John G Swales; Nicole Strittmatter; James W Tucker; Malcolm R Clench; Peter J H Webborn; Richard J A Goodwin
Journal:  Sci Rep       Date:  2016-11-24       Impact factor: 4.379

8.  Molecular imaging identifies age-related attenuation of acetylcholine in retrosplenial cortex in response to acetylcholinesterase inhibition.

Authors:  Theodosia Vallianatou; Mohammadreza Shariatgorji; Anna Nilsson; Elva Fridjonsdottir; Patrik Källback; Nicoletta Schintu; Per Svenningsson; Per E Andrén
Journal:  Neuropsychopharmacology       Date:  2019-04-22       Impact factor: 7.853

9.  Diamine oxidase knockout mice are not hypersensitive to orally or subcutaneously administered histamine.

Authors:  Matthias Karer; Marlene Rager-Resch; Teresa Haider; Karin Petroczi; Elisabeth Gludovacz; Nicole Borth; Bernd Jilma; Thomas Boehm
Journal:  Inflamm Res       Date:  2022-03-18       Impact factor: 4.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.